Join our community of smart investors

Merck quits cholesterol after drug fails to excite

Disappointing data from a final stage clinical trial has forced Merck to pull the plug on its cholesterol drug
October 18, 2017

US pharma giant, Merck (MRK) has decided not to file its anti-cholesterol drug, Anacetrapid, for approval with the US Food and Drug Administration (FDA) after it produced poor clinical trial results. The drug only managed to lower the risk of heart attack in a group of 30,000 high cholesterol patients by 9 per cent – just 1 per cent better than the placebo.

IC TIP: Buy at $63.34

Not only were the trial results unspectacular, but the cholesterol busting market is enormously competitive. Having been dominated for several decades by statins, many large pharmaceutical companies are currently working on a new generation of medicine known as PCSK9 inhibitors. These drugs have been proven to reduce cholesterol by as much as 60 per cent, significantly better than Anacetrapid.

This is subscriber only content
Start your trial to keep reading
PRINT AND DIGITAL trial

Get 12 weeks for £12
  • Essential access to the website and app
  • Magazine delivered every week
  • Investment ideas, tools and analysis
Have an account? Sign in